NCT05084963 - A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 29, 2021

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions

Eosinophilic Esophagitis

Interventions

DRUG

IRL201104

lyophilised powder for reconstitution for IV dosing

DRUG

Placebo

Matching placebo for IRL201104

Trial Locations (23)

11021

Revolo Investigational Site, Great Neck

27599

Revolo Investigational Site, Chapel Hill

27607

Revolo Investigational Site, Raleigh

27710

Revolo Investigational Site, Durham

30328

Revolo Investigational Site, Sandy Springs

32825

Revolo Investigational Site, Orlando

34653

Revolo Investigational Site, New Port Richey

37421

Revolo Investigational Site, Chattanooga

37663

Revolo Investigational Site, Kingsport

44060

Revolo Investigational Site, Mentor

48334

Revolo Investigational Site, Farmington Hills

52242

Revolo Investigational Site, Iowa City

70072

Revolo Investigational Site, Marrero

70526

Revolo Investigational Site, Crowley

72211

Revolo Investigational Site, Little Rock

77521

Revolo Investigational Site, Baytown

78550

Revolo Investigational Site, Harlingen

80112

Revolo Investigational Site, Centennial

84065

Revolo Investigational Site, Riverton

84132

Revolo Investigational Site, Salt Lake City

92563

Revolo Investigational Site, Murrieta

02111

Revolo Investigational Site, Boston

02114

Revolo Investigational Site, Boston